The alternative pathway of complement and the thrombotic microangiopathies

Transfusion and Apheresis Science

Volumn 54, Issue 2, 2016, Pages 220-231

  Teoh, Chia Wei ^a,b   Riedl, Magdalena ^b,c   Licht, Christoph ^a,b,d  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alternative complement pathway; Atypical hemolytic uremic syndrome; Eculizumab; Thrombotic microangiopathy; Treatment monitoring

Indexed keywords

AUTOANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; MONOCLONAL ANTIBODY;

ANTIBODY MEDIATED REJECTION; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; DISEASE ACTIVITY; DRUG EFFICACY; ENDOTHELIUM INJURY; FUNCTIONAL STATUS; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION; MALIGNANT HYPERTENSION; METABOLIC DISORDER; ORGAN TRANSPLANTATION; PLASMAPHERESIS; PREGNANCY; REVIEW; STEM CELL TRANSPLANTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ANEMIA, HEMOLYTIC; BLOOD; COMPLICATION; DRUG EFFECTS; THROMBOCYTOPENIA; THROMBOTIC MICROANGIOPATHIES;

ANEMIA, HEMOLYTIC; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; THROMBOCYTOPENIA; THROMBOTIC MICROANGIOPATHIES;

EID: 84965057545     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2016.04.012     Document Type: Review

References (153)

1. Riedl M, Fakhouri F, Le Quintrec M, Noone DG, Jungraithmayr TC, Fremeaux-Bacchi V, et al. Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches. Semin Thromb Hemost 2014, 40:444-464.
2. George JN, Nester CM Syndromes of thrombotic microangiopathy. NEJM 2014, 371:654-666.
3. Meri S Complement activation in diseases presenting with thrombotic microangiopathy. Eur J Intern Med 2013, 24:496-502.
4. Tsai H-M Untying the knot of thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. Am J Med 2013, 126:200-209.
5. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD Complement and coagulation: strangers or partners in crime. Trends Immunol 2007, 28:184-192.
6. Moschcowitz E An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease. Am J Med 1952, 13:567-569.
7. Knöbl P Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost 2014, 40:493-502.
8. Hassenpflug WA, Budde U, Schneppenheim S, Schneppenheim R Inherited thrombotic thrombocytopenic purpura in children. Semin Thromb Hemost 2014, 40:487-492.
9. Gasser C, Gautier E, Steck A, Siebenmann RE, Oechslin R Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 1955, 85:905-909. in German.
10. Würzner R, Riedl M, Rosales A, Orth-Höller D Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS). Semin Thromb Hemost 2014, 40:508-516.
11. Scheiring J, Rosales A, Zimmerhackl LB Clinical practice. Today's understanding of the haemolytic uraemic syndrome. Eur J Pediatr 2010, 169:7-13.
12. Walport MJ Complement (part 1). NEJM 2001, 344:1058-1066.
13. Walport MJ Complement (part 2). NEJM 2001, 344:1140-1144.
14. Rodríguez de Córdoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sánchez-Corral P The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004, 41:355-367.
15. Schmidt CQ, Herbert AP, Hocking HG, Uhrín D, Barlow PN Translational mini-review series on complement factor H: structural and functional correlations for factor H. Clin Exp Immunol 2008, 151:14-24.
16. Makou E, Herbert AP, Barlow PN Functional anatomy of complement factor H. Biochemistry 2013, 52:3949-3962.
17. Bettoni S, Bresin E, Remuzzi G, Noris M, Donadelli R Insights into the effects of complement Factor H on the assembly and decay of the alternative pathway C3 proconvertase and C3 convertase. J Biol Chem 2016, 291:8214-8230.
18. Kim DD, Song WC Membrane complement regulatory proteins. Clin Immunol 2006, 118:127-136.
19. Morgan BP, Meri S Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 1994, 15:369-396.
20. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT Complement system part I - molecular mechanisms of activation and regulation. Front Immunol 2015, 6:1-30.
21. Frimat M, Roumenina LT, Camous L, Bigot S, Lesavre P, Satchell SC, et al. Complement activation by endothelial cells treated with inflammatory cytokines or heme, in the context of atypical hemolytic uremic syndrome. Mol Immunol 2009, 46:2849.
22. Camous L, Roumenina L, Bigot S, Brachemi S, Frémeaux-Bacchi V, Lesavre P, et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011, 117:1340-1349.
23. Loirat C, Frémeaux-Bacchi V Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
24. Noris M, Remuzzi G Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
25. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
26. Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJH Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31:E1445-60.
27. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475-486.
28. Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407-415.
29. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
30. Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 2014, 85:1151-1160.
31. Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.
32. Le Quintrec M, Lionet A, Kamar N, Karras A, Barbier S, Buchler M, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008, 8:1694-1701.
33. Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, et al. Antibody mediated rejection associated with complement factor H-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant 2012, 12:2546-2553.
34. Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood 2013, 122:2003-2007.
35. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, et al. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014, 20:518-525.
36. Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood 2016, 127:989-996.
37. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013, 45:531-536.
38. Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
39. Bouts AH, Roofthooft MT, Salomons GS, Davin JC CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 2010, 25:2547-2548.
40. Geraghty MT, Perlman EJ, Martin LS, Hayflick SJ, Casella JF, Rosenblatt DS, et al. Cobalamin C defect associated with hemolytic-uremic syndrome. J Pediatr 1992, 120:934-937.
41. Komhoff M, Roofthooft MT, Teertstra T, Westra D, Losito A, van de Kar N, et al. Combined renal thrombotic microangiopathy and pulmonary arterial hypertension is caused by cobalamine C deficiency. Pediatr Nephrol 2013, 28:1374.
42. Totina A, Iorember F, El-Dahr SS, Yosypiv IV Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension. Clin Pediatr (Phila) 2013, 52:183-186.
43. Chapin J, Eyler S, Smith R, Tsai HM, Laurence J Complement factor H mutations are present in ADAMTS13-deficient, ticlopidine-associated thrombotic microangiopathies. Blood 2013, 121:4012-4013.
44. Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J 2013, 6:421-425.
45. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, et al. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013, 15:R12.
46. Chen MH, Chen WS, Mu-Hsin Chang P, Lee HT, Lin HY, Huang DF Thrombotic microangiopathy in systemic lupus erythematosus: a cohort study in North Taiwan. Rheumatology (Oxford) 2011, 50:768-775.
47. El Karoui K, Hill GS, Karras A, Jacquot C, Moulonguet L, Kourilsky O, et al. A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. J Am Soc Nephrol 2012, 23:137-148.
48. Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles. Mol Immunol 2009, 46:2801-2807.
49. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2013, 9:46-53.
50. Barbour TD, Ruseva MM, Pickering MC Update on C3 glomerulopathy. Nephrol Dial Transplant 2016, 31:717-725.
51. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int 2013, 84:1079-1089.
52. Bokenkamp A, Hoyer PF, Offner G, Helmchen U, Brodehl J Recurrent haemolytic uraemic syndrome in a boy with focal and segmental glomerulosclerosis. Eur J Pediatr 1992, 151:791-792.
53. Benz K, Amann K, Dittrich K, Dötsch J Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol 2007, 22:2125-2128.
54. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
55. Manenti L, Signorini L, Gnappi E, Pilato FP, Vaglio A, Allegri L, et al. Outcome of renal ANCA associated vasculitis (AAV) with complement hyperactivation signs: a retrospective study. Nephrol Dial Transplant 2013, 28:i1-2.
56. Manenti L, Vaglio A, Gnappi E, Maggiore U, Allegri L, Allinovi M, et al. Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis. Clin J Am Soc Nephrol 2015, 10:2143-2151.
57. Rodríguez de Córdoba S, Hidalgo MS, Pinto S, Tortajada A Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost 2014, 40:422-430.
58. Noris M, Remuzzi G Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010, 10:1517-1523.
59. Sacks SH, Zhou W The role of complement in the early immune response to transplantation. Nat Rev Immunol 2012, 12:431-442.
60. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24:687-696.
61. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016, 31:15-39.
62. Noris M, Remuzzi G Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: core curriculum 2015. Am J Kidney Dis 2015, 66:359-375.
63. Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
64. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013, 368:2169-2181.
65. Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 2015, 87:1061-1073.
66. Simonetti G, Vilalta R, Lapeyraque A-L, Gruppo R, Sherwinter J, Smith J, et al. Efficacy and safety of eculizumab treatment for atypical haemolytic uremic syndrome (aHUS) in paediatric patients: subgroup analysis of a retrospective study. Nephrol Dial Transplant 2012, 27:ii11-3.
67. Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, et al. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016, 89:701-711.
68. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012, 8:643-657. French Study Group for aHUS/C3G.
69. Zimmerhackl LB, Hofer J, Cortina G, Mark W, Würzner R, Jungraithmayr TC, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010, 362:1746-1748.
70. Zuber J, Le Quintrec M, Krid S, Bertoye C, Gueutin V, Lahoche A, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3337-3354.
71. Struijk GH, Bouts AH, Rijkers GT, Kuin EA, ten Berge IJ, Bemelman FJ Meningococcal sepsis complicating eculizumab treatment despite prior vaccination. Am J Transplant 2013, 13:819-820.
72. Bouts A, Monnens L, Davin JC, Struijk G, Spanjaard L Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy. Pediatr Nephrol 2011, 26:1919-1920.
73. Westwood JP, Langley K, Heelas E, Machin SJ, Scully M Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura. Br J Haematol 2014, 164:858-866.
74. Wu TC, Yang S, Haven S, Holers VM, Lundberg AS, Wu H, et al. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J Thromb Haemost 2013, 11:1925-1927.
75. Réti M, Farkas P, Csuka D, Rázsó K, Schlammadinger Á, Udvardy ML, et al. Complement activation in thrombotic thrombocytopenic purpura. J Thromb Haemost 2012, 10:791-798.
76. Chapin J, Weksler B, Magro C, Laurence J Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2012, 157:772-774.
77. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
78. Bu F, Maga T, Meyer NC, Wang K, Thomas CP, Nester CM, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014, 25:55-64.
79. Feng S, Eyler SJ, Zhang Y, Maga T, Nester CM, Kroll MH, et al. Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome. Blood 2013, 122:1487-1493.
80. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4:1920-1924.
81. Lapeyraque A-L, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011, 364:2561-2563.
82. Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, et al. Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 2011, 378:1166-1173.
83. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, et al. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 2012, 27:3807-3815.
84. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012, 345:e4565.
85. Ullrich S, Bremer P, Neumann-Grutzeck C, Otto H, Rüther C, von Seydewitz CU, et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS ONE 2013, 8. e55278.
86. Delmas Y, Vendrely B, Clouzeau B, Bachir H, Bui HN, Lacraz A, et al. Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab. Nephrol Dial Transplant 2014, 29:565-572.
87. Harambat J, De Charette C, Godron A, Bordes C, Delmas Y, Llanas B Eculizumab in Shiga toxin associated hemolytic uremic syndrome: a single center matched-cohort study. Pediatr Nephrol 2013, 28:1373.
88. Gitiaux C, Krug P, Grevent D, Kossorotoff M, Poncet S, Eisermann M, et al. Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 2013, 55:758-765.
89. Dhawan V, Ariyamuthu V, Malhotra K, Bichu P Renal recovery in a child with D+ HUS. Is eculizumab a typical drug?. Am J Kidney Dis 2013, 61:B37.
90. Gilbert RD, Nagra A, Haq MR Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae. Med Hypotheses 2013, 81:400-403.
91. Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, et al. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013, 28:2237-2245.
92. Bento D, Mapril J, Rocha C, Marchbank KJ, Kavanagh D, Barge D, et al. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail 2010, 32:753-756.
93. Berner R, Krausse MF, Gordjani N, Zipfel PF, Boehm N, Krueger M, et al. Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis. Pediatr Nephrol 2002, 17:190-192.
94. Obando I, Camacho MS, Falcon-Neyra D, Hurtado-Mingo A, Neth O Atypical hemolytic uremic syndrome associated with Bordetella pertussis infection. Pediatr Infect Dis J 2012, 31:1210.
95. Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 2009, 24:2752-2754.
96. Barnett ANR, Hadjianastassiou VG, Shaw OJ, Das PP, O'Donnell PJ, Chowdhury P, et al. Eculizumab for salvage in post-transplant thrombotic microangiopathy. Transpl Int 2011, 24:153.
97. Wilson CH, Brown AL, White SA, Goodship TH, Sheerin NS, Manas DM Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab. Transplantation 2011, 92:e42-3.
98. Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report. Clin Nephrol 2015, 83:125-129.
99. Commereuc M, Karras A, Amrein C, Boussaud V, Sberro-Soussan R, Guillemain R, et al. Successful treatment of acute thrombotic microangiopathy by eculizumab after combined lung and kidney transplantation. Transplantation 2013, 96:e58-9.
100. Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11:2405-2413.
101. González-Roncero F, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012, 44:2690-2694.
102. Yelken B, Arpali E, Görcin S, Kocak B, Karatas C, Demiralp E, et al. Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience. Transplant Proc 2015, 47:1754-1759.
103. Chehade H, Rotman S, Matter M, Girardin E, Aubert V, Pascual M Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient. Pediatrics 2015, 135:e551-5.
104. Fan J, Tryphonopoulos P, Tekin A, Nishida S, Selvaggi G, Amador A, et al. Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient. Am J Transplant 2015, 15:1995-2000.
105. Hale GA, Bowman LC, Rochester RJ, Benaim E, Heslop HE, Krance RA, et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005, 11:912-920.
106. Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, et al. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2016, 22:307-315.
107. Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol 2013, 161:279-280.
108. Lorcy N, Rioux-Leclercq N, Lombard ML, Le Pogamp P, Vigneau C Three kidneys, two diseases, one antibody. Nephrol Dial Transplant 2011, 26:3811-3813.
109. Brackman D, Sartz L, Leh S, Kristoffersson AC, Bjerre A, Tati R, et al. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol Dial Transplant 2011, 26:3399-3403.
110. Alfandary H, Davidovits M Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I. Pediatr Nephrol 2015, 30:2129-2134.
111. Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, et al. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol 2016, 31:683-687.
112. Sánchez-Moreno A, De la Cerda F, Cabrera R, Fijo J, López-Trascasa M, Bedoya R, et al. Eculizumab in dense-deposit disease after renal transplantation. Pediatr Nephrol 2014, 29:2055-2059.
113. Besbas N, Gulhan B, Gucer S, Korkmaz E, Ozaltin F A novel CFHR5 mutation associated with C3 glomerulonephritis in a Turkish girl. J Nephrol 2014, 27:457-460.
114. Oosterveld MJ, Garrelfs MR, Hoppe B, Florquin S, Roelofs JJ, van den Heuvel LP, et al. Eculizumab in pediatric dense deposit disease. Clin J Am Soc Nephrol 2015, 10:1773-1782.
115. Schmitt R, Krmar RT, Kristoffersson A, Söderberg M, Karpman D IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr 2011, 170:107-110.
116. Edey M, Strain L, Ward R, Ahmed S, Thomas T, Goodship TH Is complement factor H a susceptibility factor for IgA nephropathy. Mol Immunol 2009, 46:1405-1408.
117. Rosenblad T, Rebetz J, Johansson M, Békássy Z, Sartz L, Karpman D Eculizumab treatment for rescue of renal function in IgA nephropathy. Pediatr Nephrol 2014, 29:2225-2228.
118. Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, Liu LJ, et al. Rare variants in the complement factor H-related protein 5 gene contribute to genetic susceptibility to IgA nephropathy. J Am Soc Nephrol 2016, 1-12. epublication ahead of print.
119. Ring T, Pedersen BB, Salkus G, Goodship TH Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum. Clin Kidney J 2015, 8:489-491.
120. Coppo R, Peruzzi L, Amore A, Martino S, Vergano L, Lastauka I, et al. Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatr Nephrol 2015, 30:167-172.
121. Pickering MC, Ismajli M, Condon MB, McKenna N, Hall AE, Lightstone L, et al. Eculizumab as rescue therapy in severe resistant lupus nephritis. Rheumatology (Oxford) 2015, 54:2286-2288.
122. El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab. Am J Kidney Dis 2015, 65:127-130.
123. Lonze BE, Zachary AA, Magro CM, Desai NM, Orandi BJ, Dagher NN, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014, 14:459-465.
124. Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 2014, 93:e143.
125. Shapira I, Andrade D, Allen SL, Salmon JE Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012, 64:2719-2723.
126. Zikos TA, Sokolove J, Ahuja N, Berube C Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 2015, 21:311-313.
127. Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël LH, et al. Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes. Am J Transplant 2013, 13:2179-2185.
128. Sathe KP, Mehta KP Coexistence of atypical HUS with MPGN and ANCA associated vasculitis. Pediatr Nephrol 2013, 28:1554.
129. Ardissino G, Wally Ossola M, Baffero GM, Rigotti A, Cugno M Eculizumab for atypical hemolytic uremic syndrome in pregnancy. Obstet Gynecol 2013, 122:487-489.
130. Zschiedrich S, Prager EP, Kuehn EW Successful treatment of the postpartum atypical hemolytic uremic syndrome with eculizumab. Ann Intern Med 2013, 159:76.
131. Kourouklaris A, Ioannou K, Athanasiou I, Demetriou K, Panagidou A, Zavros M Postpartum atypical hemolytic uremic syndrome in a young adult treated with eculizumab. Nephrol Dial Transplant 2013, 28:i310-1.
132. Guigonis V, Frémeaux-Bacchi V, Giraudier S, Favier R, Borderie D, Massy Z, et al. Late-onset thrombocytic microangiopathy caused by cblC disease: association with a factor H mutation. Am J Kidney Dis 2005, 45:588-595.
133. Cornec-Le Gall E, Delmas Y, De Parscau L, Doucet L, Ogier H, Benoist JF, et al. Adult-onset eculizumab-resistant hemolytic uremic syndrome associated with cobalamin C deficiency. Am J Kidney Dis 2014, 63:119-123.
134. Faguer S, Huart A, Frémeaux-Bacchi V, Ribes D, Chauveau D Eculizumab and drug-induced haemolytic-uraemic syndrome. Clin Kidney J 2013, 6:484-485.
135. Ansari A, Kansal S, Chiesa-Vottero A, Simon J Doxorubicin induced thrombotic microangiopathy-2 case reports of this unknown association. Am J Kidney Dis 2013, 61:B20.
136. Al Ustwani O, Lohr J, Dy G, Levea C, Connolly G, Arora P, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol 2014, 5:E30-3.
137. Westland R, Bodria M, Carrea A, Lata S, Scolari F, Fremeaux-Bacchi V, et al. Phenotypic expansion of DGKE-associated diseases. J Am Soc Nephrol 2014, 25:1408-1414.
138. Costabile M Measuring the 50% haemolytic complement (CH50) activity of serum. J Vis Exp 2010, 37:e1923.
139. Servais G, Walmagh J, Duchateau J Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50). J Immunol Methods 1991, 140:93-100.
140. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjöholm AG, Wurzner R, et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005, 296:187-198.
141. Roumenina LT, Loirat C, Dragon-Durey MA, Halbwachs-Mecarelli L, Sautes-Fridman C, Fremeaux-Bacchi V Alternative complement pathway assessment in patients with atypical HUS. J Immunol Methods 2011, 365:8-26.
142. Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004, 41:81-84.
143. Heinen S, Pluthero FG, van Eimeren VF, Quaggin SE, Licht C Monitoring and modeling treatment of atypical hemolytic uremic syndrome. Mol Immunol 2013, 54:84-88.
144. Volokhina EB, van de Kar NC, Bergseth G, van der Velden TJ, Westra D, Wetzels JF, et al. Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. Clin Immunol 2015, 160:237-243.
145. Cugno M, Gualtierotti R, Possenti I, Testa S, Tel F, Griffini S, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Thromb Haemost 2014, 12:1440-1448.
146. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, Xhaard A, Rosain J, Castaneda DC, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015, 125:775-783.
147. Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 2014, 124:1715-1726.
148. Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, et al. A new paradigm: diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev 2015, 29:191-204.
149. Prüfer F, Scheiring J, Sautter S, Jensen DB, Treichl R, Würzner R, et al. Terminal complement complex (C5b-9) in children with recurrent hemolytic uremic syndrome. Semin Thromb Hemost 2006, 32:121-127.
150. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 2014, 123:3733-3738.
151. Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle AP, Ogawa M, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood 2015, 125:3253-3262.
152. Sheerin NS, Kavanagh D, Goodship TH, Johnson S A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016, 109:27-33.
153. Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 2015, 66:171-172.